Key Points
- CFO Cecilia Jones sold 2,932 shares on Dec. 30 at an average price of $27.09 for about $79,428, reducing her stake by 7.27% to 37,394 shares valued at roughly $1.01 million.
- Agios shares trade near $27 with a 1‑year range of $22.24–$46.00 and a $1.58 billion market cap; the company remains unprofitable (negative PE and margins) despite recent revenue growth and a quarterly EPS beat.
- Analyst views are mixed — price targets span widely (Goldman $25, HC Wainwright $62) but the consensus is a "Moderate Buy" with an average target of $38.89.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 2,932 shares of the company's stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the sale, the chief financial officer owned 37,394 shares of the company's stock, valued at $1,013,003.46. This trade represents a 7.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Agios Pharmaceuticals Stock Performance
Shares of AGIO stock opened at $27.18 on Friday. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The business's fifty day moving average is $32.20 and its 200-day moving average is $35.96. The stock has a market cap of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. The business had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The company's revenue was up 43.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $16.22 earnings per share. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on AGIO shares. The Goldman Sachs Group lowered their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a "neutral" rating on the stock in a research note on Thursday, November 20th. HC Wainwright raised their target price on shares of Agios Pharmaceuticals from $48.00 to $62.00 and gave the stock a "buy" rating in a report on Wednesday, December 24th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Agios Pharmaceuticals in a report on Monday. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 22nd. Finally, Leerink Partners lifted their target price on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, December 26th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $38.89.
Read Our Latest Analysis on Agios Pharmaceuticals
Institutional Trading of Agios Pharmaceuticals
Hedge funds have recently modified their holdings of the business. Bellevue Group AG boosted its position in shares of Agios Pharmaceuticals by 3.5% in the third quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company's stock worth $149,110,000 after buying an additional 124,586 shares during the period. Erste Asset Management GmbH lifted its stake in Agios Pharmaceuticals by 18.8% in the 3rd quarter. Erste Asset Management GmbH now owns 2,764,900 shares of the biopharmaceutical company's stock worth $108,578,000 after acquiring an additional 438,411 shares in the last quarter. Wellington Management Group LLP lifted its stake in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company's stock worth $99,203,000 after acquiring an additional 2,049,287 shares in the last quarter. Commodore Capital LP boosted its position in Agios Pharmaceuticals by 0.6% during the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company's stock worth $93,859,000 after acquiring an additional 13,287 shares during the period. Finally, TCG Crossover Management LLC grew its stake in Agios Pharmaceuticals by 105.2% during the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company's stock valued at $57,402,000 after acquiring an additional 733,038 shares in the last quarter.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
